National Resource for Translational and Developmental Proteomics

国家转化和发育蛋白质组学资源

• 批准号: 9283567
• 负责人: NEIL L KELLEHER
• 金额: $ 113.13万
• 依托单位: NORTHWESTERN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-08-01 至 2020-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9283567
• 关键词: Acute Myelocytic Leukemia; Address; American; Area; Atherosclerosis; Automobile Driving; Back; Biological; Biomedical Technology; Cancer Patient; Cancer Survivor; Cardiovascular Diseases; Chicago; Chronic Lymphocytic Leukemia; Clinical Research; Collaborations; Computer software; Coronary heart disease; Country; Data Collection; Development; Diagnostic; Disease; Feedback; Fertility; Foundations; Fourier Transform; Fractionation; Funding; Generations; Goals; Graft Rejection; Histones; Housing; Information Technology; Institutes; International; Investments; Kidney Transplantation; Laboratories; Leadership; Letters; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Medical; Multiple Myeloma; Myocardial Infarction; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; Nature; Oocytes; Organ Transplantation; Outcome; Paper; Patients; Performance; Positioning Attribute; Process; Protein Analysis; Proteins; Proteomics; Public Health; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Route; Sampling; Science; Secure; Services; TP53 gene; Technology; Time; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Validation; Vision; Woman; arm; base; biological research; biomarker discovery; cohort; exhaustion; fertility improvement; focus ultra; graft failure; improved; innovation; instrument; interest; liver transplantation; mouse model; new technology; next generation; novel; oncofertility; organ regeneration; outreach; pre-clinical research; public health relevance; research and development; technology development; training project; visiting scholar

 DESCRIPTION (PROVIDED BY APPLICANT): Here we propose a National Resouce for Translational and Developmental Proteomics (NRTDP). The science drivers are outlined in eight Driving Biomedical Projects that motivate the specific aims for four Technology Research and Development Projects. The impact of these combined activities, devoted to improving mass spectrometry-based proteomics using whole proteins as the primary unit of measurement, will be substantial. Integrated over all aspects of the resource (including biomedical application, technology development, dissemination and training), the projected impacts are aligned with both the spirit and the letter of a P41 Biomedical Technology Research Resource and the strategic goals of the NIH as a whole. Applying innovation to timely challenges in diverse areas of clinical and translational research will secure a leadership position for our nation in 'next-generation' proteomics technology. These technologies will serve driving projects and investigators to improve scientific understanding and diagnostics, ultimately improving the lives of cancer patients, recipients of kidney transplants, those afflicted with coronary heart disease, and to preserve fertility in women survivors of cancer (oncofertility). More specifically, we will focus ultra-high performance proteomics on sample sets deriving from research on various cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. In technology, we will accelerate the development of the leading platform for top-down proteomics, including two new Fourier-Transform instruments, new protein fractionation technologies, and the AUTOPILOT software suite to allow strategic objectives of biomedical projects to govern the most detailed aspects of data collection on a daily basis. A tailored workflow to enable pervasive and exhaustive analysis of core histones further augments the technology portfolio available in this deeply collaborative and deferential national resource housing a demonstrably high performing technical and administrative team. Good evidence of the team's ability to distill high-end research activities into robust servce lines is now visible. Interest in the laboratory as a hub for training has been robust (with over a dozen visiting scholars to date) and specific plans for expansion of these activities are included. Several routes of information and technology dissemeniation also described in the application. The administration and execution of all these activities is assured by a proven senior team operating the Proteomics Center of Excellence (PCE) at Northwestern, which also has very strong institutional backing to align proteomics ongoing in Chicago with national priorities of NIH-funded biological and translational research of the NIH. The advancement of general medical science envisioned here will be of interest to several institutes including NCI, NICHD, NIDDK, NIGMS, and NHLBI - all of which are heavily invested in proteomics research. Our team of senior researchers at the Proteomics Center of Excellence, along with over a dozen collaborating laboratories around the country, look forward to feedback regarding the proposed NRTDP.

 描述（由申请人提供）：在这里，我们提出了一个全国性的转化和发展蛋白质组学（NRTDP）。在八个驾驶生物医学项目中概述了科学驱动因素，这些项目融合了四个技术研发项目的特定目的。这些组合活性的影响，致力于使用整个蛋白作为测量的主要单位来改善基于质谱的蛋白质组学，这将是重要的。整合了资源的各个方面（包括生物医学应用，技术开发，传播和培训），预计的影响与P41生物医学技术研究资源的精神和字母保持一致，以及NIH的战略目标。将创新应用于临床和转化研究的潜水区域的及时挑战，将确保我们国家在“下一代”蛋白质组学技术中的领导地位。这些技术将为驾驶项目和研究人员提供服务，以改善科学的理解和诊断，最终改善癌症患者的生活，肾脏移植的接受者，患有冠状动脉心脏病的人的生活以及维护癌症妇女生存的生育能力。更具体地说，我们将把超高的性能蛋白质组学集中在对各种癌症研究的样本集上，包括慢性淋巴细胞性白血病，多发性骨髓瘤和急性髓性白血病。在技​​术中，我们将加快自上而下蛋白质组学的领先平台的开发，包括两种新的傅立叶转换仪器，新的蛋白质分级技术和自动驾驶仪软件套件，以允许生物医学项目的战略目标，以每天管理最详细的数据收集方面。量身定制的工作流程，以实现对核心组蛋白的普遍和详尽的分析，进一步增强了这种深入的协作和有尊敬的国家资源所提供的技术组合，这表明了高性能的技术和行政团队。现在可以看到该团队将高端研究活动提炼为强大的服务线的充分证据。 对实验室作为培训枢纽的兴趣非常强大（迄今为止有十几个访问学者），包括这些活动扩展的具体计划。应用程序中还描述了几种信息和技术传播途径。所有这些活动的管理和执行是由在西北地区经营蛋白质组学卓越中心（PCE）的经过验证的高级团队来承担的，该团队在芝加哥正在进行的蛋白质组学与NIH资助的NIH国家的国家优先事项和NIH的全国优先事项相结合。 NCI，NICHD，NIDDK，NIGMS和NHLBI在内的多家机构将有意义的一般医学科学的进步 - 所有这些机构都大量投资于蛋白质组学研究。我们的蛋白质组学卓越中心高级研究人员团队以及全国各地的十几个合作实验室，期待有关拟议的NRTDP的反馈。